A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
This study has been completed.
NCIC Clinical Trials Group
Cascadian Therapeutics Inc.
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )
First received: December 9, 2010
Last updated: April 10, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 2015|
|Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, Squire J, Tsao MS, Kamel-Reid S, Banerji S, Tu D, Powers J, Hausman DF, Mason WP. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015 Sep;17(9):1270-4. doi: 10.1093/neuonc/nou365.